

Disclosures under Regulation 10(6) - Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Ranbaxy Laboratories Limited			
2.	Name of the acquirer(s)	Sun Pharmaceutical Industries Limited			
3.	Name of the stock exchange where shares of the TC are listed	BSE Limited National Stock Exchange of India Limited			
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Pursuant to Scheme of Arrangement for merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited being effective on March 24, 2015			
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10 (1)(d)(ii)			
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Not Applicable			
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)		Whether the disclosures under regulation 10(5) are actually made	
	a. Name of the transferor / seller	Pursuant to Scheme of Arrangement for merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited being effective on March 24, 2015			
	b. Date of acquisition				
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above				
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC				
	e. Price at which shares are proposed to be acquired / actually acquired				
8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a Sun Pharmaceutical Industries Limited	0	0	0	0
	b Silverstreet Developers LLP	6967542	1.64	0#	0

#Due to merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries Limited.

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

For Sun Pharmaceutical Industries Limited

A B

**Ashok Bhuta
Compliance Officer**


